These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 7591118)

  • 1. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.
    Rosenqvist E; Høiby EA; Wedege E; Bryn K; Kolberg J; Klem A; Rønnild E; Bjune G; Nøkleby H
    Infect Immun; 1995 Dec; 63(12):4642-52. PubMed ID: 7591118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine.
    Naess LM; Aarvak T; Aase A; Oftung F; Høiby EA; Sandin R; Michaelsen TE
    Vaccine; 1999 Feb; 17(7-8):754-64. PubMed ID: 10067680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.
    Rosenqvist E; Harthug S; Frøholm LO; Høiby EA; Bøvre K; Zollinger WD
    J Clin Microbiol; 1988 Aug; 26(8):1543-8. PubMed ID: 3139705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.
    Wedege E; Høiby EA; Rosenqvist E; Bjune G
    Infect Immun; 1998 Jul; 66(7):3223-31. PubMed ID: 9632589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.
    Beernink PT; Ispasanie E; Lewis LA; Ram S; Moe GR; Granoff DM
    J Infect Dis; 2019 Mar; 219(7):1130-1137. PubMed ID: 30346576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.
    Oftung F; Naess LM; Wetzler LM; Korsvold GE; Aase A; Høiby EA; Dalseg R; Holst J; Michaelsen TE; Haneberg B
    Infect Immun; 1999 Feb; 67(2):921-7. PubMed ID: 9916109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.
    Borrow R; Aaberge IS; Santos GF; Eudey TL; Oster P; Glennie A; Findlow J; Høiby EA; Rosenqvist E; Balmer P; Martin D
    Clin Diagn Lab Immunol; 2005 Aug; 12(8):970-6. PubMed ID: 16085915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.
    Rosenqvist E; Høiby EA; Bjune G; Bryn K; Closs O; Feiring B; Klem A; Nøkleby H; Frølm LO
    NIPH Ann; 1991 Dec; 14(2):169-79; discussion 180-1. PubMed ID: 1687481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.
    Tappero JW; Lagos R; Ballesteros AM; Plikaytis B; Williams D; Dykes J; Gheesling LL; Carlone GM; Høiby EA; Holst J; Nøkleby H; Rosenqvist E; Sierra G; Campa C; Sotolongo F; Vega J; Garcia J; Herrera P; Poolman JT; Perkins BA
    JAMA; 1999 Apr; 281(16):1520-7. PubMed ID: 10227322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.
    Naess LM; Oftung F; Aase A; Wetzler LM; Sandin R; Michaelsen TE
    Infect Immun; 1998 Mar; 66(3):959-65. PubMed ID: 9488382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.
    Wedege E; Kuipers B; Bolstad K; van Dijken H; Frøholm LO; Vermont C; Caugant DA; van den Dobbelsteen G
    Infect Immun; 2003 Jul; 71(7):3775-81. PubMed ID: 12819059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.
    Fischer M; Carlone GM; Holst J; Williams D; Stephens DS; Perkins BA
    Vaccine; 1999 May; 17(19):2377-83. PubMed ID: 10392619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.
    Feiring B; Fuglesang J; Oster P; Naess LM; Helland OS; Tilman S; Rosenqvist E; Bergsaker MA; Nøkleby H; Aaberge IS
    Clin Vaccine Immunol; 2006 Jul; 13(7):790-6. PubMed ID: 16829617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.
    Wedege E; Bolstad K; Aase A; Herstad TK; McCallum L; Rosenqvist E; Oster P; Martin D
    Clin Vaccine Immunol; 2007 Jul; 14(7):830-8. PubMed ID: 17494638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A linear B-cell epitope on the class 3 outer-membrane protein of Neisseria meningitidis recognized after vaccination with the Norwegian group B outer-membrane vesicle vaccine.
    Delvig AA; Wedege E; Caugant DA; Dalseg R; Kolberg J; Achtman M; Rosenqvist E
    Microbiology (Reading); 1995 Jul; 141 ( Pt 7)():1593-600. PubMed ID: 7551027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial.
    Rollier CS; Dold C; Marsay L; Linder A; Green CA; Sadarangani M; Norheim G; Derrick JP; Feavers IM; Maiden MCJ; Pollard AJ
    mSphere; 2022 Feb; 7(1):e0067421. PubMed ID: 35080470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; van Limpt CJ; de Groot R; van Alphen L; van Den Dobbelsteen GP
    Infect Immun; 2002 Feb; 70(2):584-90. PubMed ID: 11796586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; Kuipers AJ; van Limpt CJ; Keijzers WC; van der Ende A; de Groot R; van Alphen L; van den Dobbelsteen GP
    Infect Immun; 2003 Apr; 71(4):1650-5. PubMed ID: 12654777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.
    Holst J; Feiring B; Fuglesang JE; Høiby EA; Nøkleby H; Aaberge IS; Rosenqvist E
    Vaccine; 2003 Jan; 21(7-8):734-7. PubMed ID: 12531351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.
    Haneberg B; Dalseg R; Wedege E; Høiby EA; Haugen IL; Oftung F; Andersen SR; Naess LM; Aase A; Michaelsen TE; Holst J
    Infect Immun; 1998 Apr; 66(4):1334-41. PubMed ID: 9529050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.